|
|
|
|
|
Wanbin Zhang Group |
||||||
|
||||||
| Modern Organic Synthesis and Catalysis | ||||||
| Recent Progress and News | ||
"Ir/Cu Dual Catalysis: Enantio- and Diastereodivergent Access to α,α-Disubstituted α-Amino Acids Bearing Vicinal Stereocenters". Recently published by J. Am. Chem. Soc. Congratulations! |
||
"Stereoselective and Site-specific Allylic Alkylation of Amino Acids and Small Peptides via a Pd/Cu Dual Catalysis". Recently published by J. Am. Chem. Soc. Congratulations! |
||
|
"An Ir/Zn Dual Catalysis for Enantio- and Diastereodivergent α-Allylation of α-Hydroxyketones". Recently published by J. Am. Chem. Soc. Congratulations! |
Congratulations! |
||
| Merck & Co. received the 2020 Green Chemistry Challenge Awards for improving the process used to produce certain antiviral drugs (asymmetric phosphorylation using the chiral bicyclic imidazole catalyst). | ||
Our bicyclic imidazazole nuleophilic catalyst (J. Am. Chem. Soc., 2010, 132, 15939-15941.) has been used and modified by Merck to prepare a chiral phosphoramidate, MK-3682, which is currently in Phase III clinical trials for treating hepatitis C. This work was published recently in Science (Science, 2017, 356, 426-430.) and highlighted by C&EN (C&EN, 2017, 95, 5.) as well as X-MOL News. 1 |
||
Our research about "Highly Efficient Synthesis of Qinghaosu (Artemisinin)" was reported by CCTV News (2012-08-14). This research was chosen as one of the "Top Ten Important Scientific and Technological News of China" (2012-12-28) and also chosen as one of the "Shanghai's Top Ten Scientific and Technological Achievements in 2012" (2013-05-02). The pilot plant test of 10 kilogram scale (500 L) has been successfully completed and our technology has been transferred to a company(2016-12-31). 1 |
||
All positions are available! |
||
